Risking It All? Risk-Based Monitoring at Cancer Research UK

Published on: 

Pharmaceutical Executive

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials.

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches can bring greater than 20% efficiency savings in the monitoring of early phase oncology trials, which were previously believed to be unsuitable for RBM.

Advertisement

Sherraine Hurd explains the process of moving to RBM in this Applied Clinical Trials article.